Several medications approved to treat alcohol and opioid use disorders also appear to reduce suicidality and crime during treatment, reported a study in AJP in Advance.
Researchers examined data for more than 21,000 individuals in Sweden who received treatment with at least one medication for alcohol or opioid use disorder (acamprosate, naltrexone, methadone, or buprenorphine) between 2005 and 2013. The researchers followed the individuals for an average of 7.6 years and tracked suicidal behavior or death from suicide, accidental overdoses, and arrests/convictions. Researchers compared outcomes for individuals while they were in treatment compared with when they were not in treatment.
While rates of illicit opioid use are similar across the United States and Sweden, only 15% to 20% of opioid users in the United States receive treatment, while more than 70% of those in Sweden do, noted author Yasmina Molero, Ph.D., from the Department of Psychiatry at the University of Oxford and colleagues.
Acamprosate: There were no significant differences in suicidal behavior, accidental overdoses, overall arrests, and arrests for violent crime when people received acamprosate treatment compared with periods when they did not.
Naltrexone: People were less likely to accidentally overdose during periods when receiving naltrexone treatment compared with periods they were not (hazard ratio=0.82). However, the medication was not associated with a significant reduction in suicidality or arrests.
Buprenorphine: Buprenorphine was associated with reductions in accidental overdoses (hazard ratio=0.75) and arrests in all crime categories (violent, nonviolent, and substance-related).
Methadone: There were significant reductions in the rate of suicidal behaviors (hazard ratio=0.60) and overall arrests among individuals who received methadone during periods when they were taking the medication compared with when they were not. However, there was an increased risk for accidental overdoses (hazard ratio=1.25).